← Back to Clinical Trials
Recruiting NCT06200116

NCT06200116 Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06200116
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Malignant Solid Neoplasm
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2024-12-02
Primary Completion 2026-11-30

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Non-Interventional Study

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2024-12-02 with a primary completion date of 2026-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study measures the utility of a novel artificial intelligence (AI) algorithm for performing auto-segmentation of computed tomography (CT) scans for radiation therapy planning.

Eligibility Criteria

Inclusion Criteria: * Employment at Mayo Clinic Arizona, Florida, or Rochester (which includes Regional Practice sites located at Mayo Clinic Health System locations) as train clinical staff that participate in normal tissue segmentation Exclusion Criteria: * Inability to complete study surveys

Contact & Investigator

Central Contact

Clinical Trials Referral Office

✉ mayocliniccancerstudies@mayo.edu

📞 855-776-0015

Principal Investigator

Doug J. Moseley, PhD

PRINCIPAL INVESTIGATOR

Mayo Clinic in Rochester

Frequently Asked Questions

Who can join the NCT06200116 clinical trial?

This trial is open to participants of all sexes, studying Malignant Solid Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06200116 currently recruiting?

Yes, NCT06200116 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.

Where is the NCT06200116 trial being conducted?

This trial is being conducted at Scottsdale, United States, Jacksonville, United States, Albert Lea, United States, Mankato, United States and 3 additional locations.

Who is sponsoring the NCT06200116 clinical trial?

NCT06200116 is sponsored by Mayo Clinic. The principal investigator is Doug J. Moseley, PhD at Mayo Clinic in Rochester. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology